|Bid||227.51 x 1100|
|Ask||229.70 x 800|
|Day's Range||231.06 - 234.73|
|52 Week Range||197.75 - 286.72|
|Beta (5Y Monthly)||0.84|
|PE Ratio (TTM)||84.31|
|Earnings Date||Feb 04, 2021 - Feb 08, 2021|
|Forward Dividend & Yield||3.16 (1.36%)|
|Ex-Dividend Date||Sep 08, 2020|
|1y Target Est||273.93|
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced new reporting capabilities for COVID-19 data, enabling scheduled reports to be generated from BD Synapsys™ Informatics (version 3.84).
The many of us who are unwilling to leave our homes to get a coronavirus test now have a home testing solution authorized by the Food and Drug Administration. The agency announced earlier this week that it has granted Emergency Use Authorization (EUA) for in-home use to Lucira Health's COVID-19 All-In-One test kit. According to Lucira, a privately held company, the test is a single-use prescription product.
BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, announced today that it will present at the Evercore ISI 3rd Annual HealthCONx Virtual Conference on Wednesday, December 2, 2020, at 8:00 a.m. ET.